MOESM2 of Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors Michael Gowen Keith Giles Danny Simpson Jeremy Tchack Hua Zhou Una Moran Zarmeena Dawood Anna Pavlick Shaohui Hu Melissa Wilson Hua Zhong Michelle Krogsgaard Tomas Kirchhoff Iman Osman 10.6084/m9.figshare.6072518.v1 https://springernature.figshare.com/articles/journal_contribution/MOESM2_of_Baseline_antibody_profiles_predict_toxicity_in_melanoma_patients_treated_with_immune_checkpoint_inhibitors/6072518 Additional file 2: Table S2. Patient characteristics for reproducibility cohort (n = 10). Summary of clinical features from independent group of 10 melanoma patients treated with anti-CTLA-4 (n = 3), anti-PD-1 (n = 3), or combined anti-CTLA-4/anti-PD-1 (n = 4), and from whom serum samples were used to assess assay reproducibility. LDH, lactate dehydrogenase; POD, progression of disease; SD, stable disease; PR, partial response; CR, complete response; UNC, unclassified. 2018-04-02 05:00:00 Melanoma Immunotherapy Antibodies Toxicity Biomarker